DNTH
Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) has 4 SEC Form 4 filings (24 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 13, 2026.
Insiders have net sold $9.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Marino Garcia
- Employees:78
- HQ:New York City, NY, US
- IPO:2018-06-21
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$16.5M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$5.5B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Savitz RyanFirst filing | EVP, CFO & CBO | Sale | 31,249 | $3.2M | Jul 13 | SEC ↗ |
Veness Adam MFirst filing | SVP, General Counsel and Sec. | Sale | 30,000 | $2.4M | Jun 18 | SEC ↗ |
CARR EDWARDFirst filing | CHIEF ACCOUNTING OFFICER | Sale | 43,682 | $3.6M | Mar 13 | SEC ↗ |
Randhawa SimratFirst filing | EVP, Head of R&D | Sale | 87,507 | $3.2M | Nov 14 | SEC ↗ |
Randhawa SimratFirst filing | EVP, Head of R&D | Sale | 109,031 | $4.2M | Nov 14 | SEC ↗ |
Related companies
Dianthus Therapeutics, Inc. is in the Healthcare sector.